Price
CHART BY
Frequently asked questions
What is Upstream Bio's market capitalization?
The market capitalization of Upstream Bio is $343.39M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Upstream Bio?
Upstream Bio's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$2.902. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Upstream Bio's stock?
Currently, 9 analysts cover Upstream Bio's stock, with a consensus target price of $38.43. Analyst ratings provide insights into the stock's expected performance.
What is Upstream Bio's revenue over the trailing twelve months?
Over the trailing twelve months, Upstream Bio reported a revenue of $3.32M.
What is the EBITDA for Upstream Bio?
Upstream Bio's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$171.77M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Upstream Bio?
Upstream Bio has a free cash flow of -$140.13M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Upstream Bio have, and what sector and industry does it belong to?
Upstream Bio employs approximately 75 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Upstream Bio's shares?
The free float of Upstream Bio is 36.23M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $343.39M
- EPS (TTM)
- -$2.902
- Free Float
- 36.23M
- Revenue (TTM)
- $3.32M
- EBITDA (TTM)
- -$171.77M
- Free Cashflow (TTM)
- -$140.13M
Pricing
- 52W span
- $5.86$33.62
Analyst Ratings
The price target is $38.43 and the stock is covered by 9 analysts.
Buy
7
Hold
2
Sell
0
Information
Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It develops verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin. The company was founded in April 2021 and is headquartered in Waltham, MA.
- Employees
- 75
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- UPB
Fundamentals & EOD data from FactSet